Category Archives: MERCK WatchMerck could increase the size of the dividend payment it makes to shareholders every quarter following its $41.1 billion purchase of rival Schering-Plough, although the company will not commit to an increase now.
Chief Financial Officer Peter Kellogg told analysts and investors Thursday that Merck “will be generating a lot of cash” and that the company does see the need to “ultimately make sure shareholders benefit from that.” He also said, “It’s too early to declare how we will do that.”
Merck published fake journal The following is an excerpted article that was originally published in TheScientist.com. To read the full article, with citations, click on the hyper link below. The Inconvenient Woman thought it was very important to illustrate the prevasive corporate culture of deception that has taken over the once respected Pharma Giant, Merck. [...]
Merck to buy Schering-Plough in $41 billion deal Reported by David Jolly Publ With the purchase, Merck is expanding its franchise in cardiovascular, respiratory and oncology drugs and shoring up its research pipeline, in particular with a Schering-Plough product called TRA, a promising drug designed to prevent blood clotting. In addition, Merck will benefit from the [...]
The forth quarter earning reports, the report card for publicly held companies, held no good news for Merck or its stockholders. Merck released its not overly optimistic guidance for 2009 that forecasted earnings and revenue below that expected by Wall Street analysts. It is never a good to disappoint ‘the street.’ Merck named lower sales of its Vytorin and Zetia cholesterol pills, sold as part of a joint venture with Schering-Plough as one reason for declining profit.
Merck’s total sales will drop 1% to $23.9 billion next year, according to analyst John Boris at Citigroup. He’s bullish because the stock is so cheap, but in a recent report, he laid out the challenge Merck will face in 2009: Sales of top-seller Singulair, for allergies and asthma, will barely grow because of safety worries, and generics maker Teva Pharmaceuticals (nasdaq: TEVA – news – people ) could launch a copycat ahead of schedule. The company’s vaccines division has stumbled due to manufacturing and marketing issues that executives need to fix–fast.
Merck instantly became the poster child for Big Pharma’s woes. The stock plunged 40 percent within a couple weeks. The company then suffered through a volatile 2005 — the year that Richard Clark succeeded Raymond Gilmartin as chief executive – before beginning its comeback last year.
© 2002- An Inconvenient Woman. Site design and construction by Pleiades Publishing Services, Co.
Powered by Wordpress and based on the template design MyJournal Hypereal by 
BlogoSquare
